The type I interferon system in idiopathic inflammatory myopathies

Autoimmunity

Volumn 43, Issue 3, 2010, Pages 239-243

  Lundberg, Ingrid E ^a   Barbasso Helmers, Sevim ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

IFN I; IFN signature; Inflammation; MHC; Myopathies

Indexed keywords

AUTOANTIBODY; INTERFERON; JO 1 ANTIBODY; LA ANTIBODY; RO ANTIBODY;

ARTHRITIS; CONFERENCE PAPER; DERMATOMYOSITIS; DIABETES MELLITUS; DISEASE ACTIVITY; GENE EXPRESSION; HUMAN; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; INFLAMMATORY CELL; INFLAMMATORY DISEASE; INTERFERON INDUCTION; INTERSTITIAL LUNG DISEASE; MUSCLE TISSUE; MUSCLE WEAKNESS; MYOSITIS; NONHUMAN; POLYMYOSITIS; PROTEIN EXPRESSION; VIRUS INFECTION;

ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON TYPE I; MYOSITIS; RIBONUCLEOPROTEINS;

EID: 77951464574     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903510955     Document Type: Conference Paper

References (26)

1. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000;97(16):9209-9214.
2. Salomonsson S, Grundtman C, Zhang SJ, Lanner JT, Li C, Katz A, Wedderburn LR, Nagaraju K, Lundberg IE, Westerblad H. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slowtwitch muscle. Muscle Nerve 2009;39(5):674-682.
3. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57(5):664-678.
4. Halloran PF, Urmson J, Van der Meide PH, Autenried P. Regulation of MHC expression in vivo. II. IFN-alpha/beta inducers and recombinant IFN-alpha modulate MHC antigen expression in mouse tissues. J Immunol 1989;142(12): 4241-4247.
5. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Q J Med 1998;91(6):393-399.
6. Venezia G, Licata A, Di Marco V, Craxi A, Almasio PL. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Dig Liver Dis 2005;37(11): 882-885.
7. Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol (Northwood, London, England) 2000;17(1):64-69.
8. Somani AK, Swick AR, Cooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008;144(10):1341-1349.
9. Isenberg DA, Rowe D, Shearer M, Novick D, Beverley PC. Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 1986;63(2):450-458.
10. Greenberg SA, Sanoudou D, Haslett JN, Kohane IS, KunkelLM,BeggsAH, et al.Molecular profiles of inflammatory myopathies. Neurology 2002;59(8):1170- 1182.
11. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: A novel model of pathogenesis. J Immunol 2002;168(8):4154-4163.
12. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56(11):3784-3792.
13. Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheumat 2007;56(5):1658-1668.
14. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13(1-2):59-68.
15. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjogren's syndrome: A possible etiopathogenic mechanism. Arthritis Rheum 2005;52(4):1185-1195.
16. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50(6):1861-1872.
17. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70(6):360-374.
18. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56(9):3112-3124.
19. Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tuting T. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exper Dermatol 2006; 31(4):576-582.
20. Krystufková O, Vallerskog T, Barbasso Helmers S, Mann H, Putová I, Belácek J, Malmström V, Trollmo C, Vencovsky J, Lundberg IE. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 2009;68(6):836-843.
21. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20(6): 785-798.
22. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunol 2002;3(9):822-829.
23. Barbasso Helmers S, Englund P, Engström M, Ahlin E, Fathi M, Janciauskiene S, Heimbürger M, Rönnelid J, Lundberg IE. Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum 2009;60(8):2524-2530.
24. Reefman E, Kuiper H, Limburg PC, Kallenberg CG, Bijl M. Type I interferons are involved in the development of UVB-induced inflammatory skin lesions in systemic lupus erythematosus (SLE) patients. Ann Rheum Dis 2008;67(1): 11-18.
25. DastmalchiM, GrundtmanC, AlexandersonH,Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67(12):1670-1677.
26. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007;56(12):3995-4004